Insider · CIK 0001121404
Sanofi
Files at LTGO (Latigo Biotherapeutics, Inc.), ATTO (Attovia Therapeutics, Inc.). First filing Aug 7, 2026, latest Aug 7, 2026.
In brief
Sanofi files SEC Form 4 as 10% owner at ATTO (Attovia Therapeutics, Inc.), and also at LTGO (Latigo Biotherapeutics, Inc.). Since Aug 7, 2026, Sanofi has reported 1 open-market buy worth $5.1M and 0 open-market sells worth $0, the latest filed on Aug 7, 2026.
A track record needs three past buys with six months of prices behind them; Sanofi has 0, so none is measured yet.
The newest scored trade: bought $5.1M of ATTO on Aug 6, 2026, filed Aug 7, 2026, scored 53 (moderate). In the last 12 months: 1 buy worth $5.1M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ATTO: Attovia Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 53Moderate | Attovia Therapeutics, Inc. | $5.1M 300,000 shares | +38% | - |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See footnote | +494,800 | - | - | 494,800 | Aug 12, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See footnote | +177,978 | - | - | 672,788 | Aug 12, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnote | -494,800 | - | - | 0 | Aug 12, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Convertible Promissory Notederivativeindirect: See footnote | -177,978 | - | - | 0 | Aug 12, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Common Stockindirect: See footnote | +782,855 | - | - | 782,855 | Aug 7, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnote | +300,000 | $17.00 | $5.1M | 1,082,855 | Aug 7, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnote | -782,855 | - | - | 0 | Aug 7, 2026 |
Questions about Sanofi
Answered from the filings on this page, as of the latest one.
Is Sanofi buying or selling?
In the last 12 months Sanofi reported 1 open-market buy worth $5.1M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $5.1M of ATTO on Aug 6, 2026. Grants, option exercises and tax withholding are not counted.
How did Sanofi's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sanofi has 0.
Where does Sanofi file Form 4?
Sanofi has filed Form 4 at ATTO (Attovia Therapeutics, Inc.); LTGO (Latigo Biotherapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.